Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses therapies available for patients with indolent B-cell Non-Hodgkin lymphoma.

The combination of lenalidomide and rituximab demonstrated an objective response rate of 92% as initial therapy for patients with mantle cell lymphoma.

Novel agents have transformed the treatment of mantle cell lymphoma and tumor profiling is poised to further enhance these benefits.

Laurie H. Glimcher, MD, discusses the promise of XBP1 inhibition as an immunotherapy strategy in ovarian cancer.

Andrew Dannenberg, MD, professor of Medicine, Weill Cornell Medical College, discusses the association between breast inflammation and breast cancer risk.

The Nobel Prize winning director of the National Cancer Institute, Harold Varmus, MD, has tendered his resignation to pursue research interests in New York.

A wearable device that uses electric fields to disrupt the activity of cancer cells has demonstrated survival benefits among patients with recurrent glioblastoma multiforme in real-world settings, particularly among individuals treated in earlier stages of progression

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use of interferons in myeloproliferative neoplasms.

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.